Suppression of proatherogenic leukocyte interactions by MCS-18 - Impact on advanced atherosclerosis in ApoE-deficient mice.

•The herbal product MCS-18 reduces plaque burden in advanced murine atherosclerosis.•MCS-18 promotes an increased plaque stability of advanced lesions in ApoE −/− mice.•MCS-18 decreases endothelial expression of ICAM-1 and intracellular NF-κB-p65.•MCS-18 reduces human DC migration and expression of CD209 and CCR7 by DCs.•MCS-18 suppresses human DC adhesion to an endothelial cell monolayer.